Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026)
Lexeo Therapeutics (LXEO) reported Depreciation & Amortization (CF) of $73000.0 for Q1 2026, up 21.67% on a YoY basis from $60000.0 in Q1 2025, and little changed sequentially from $73000.0 in Q4 2025.
Lexeo Therapeutics (LXEO) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Lexeo Therapeutics (LXEO) has 5 years of Depreciation & Amortization (CF) data on file, last reported at $73000.0 in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 21.67% year-over-year to $73000.0; the trailing twelve-month figure through Mar 2026 stood at $281000.0 (down 4.75% YoY), and the FY2025 full-year result was $268000.0, down 11.84% from the prior year.
- Depreciation & Amortization (CF) steadied at $73000.0 in Q1 2026, from $73000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $83000.0 in Q3 2024 to a low of $57000.0 in Q1 2023.
- A 5-year average of $69571.4 and a median of $73000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) soared 32.76% in 2023 and decreased 19.48% in 2025, its largest moves.
- Tracing LXEO's Depreciation & Amortization (CF) over 5 years: stood at $58000.0 in 2022, then surged by 32.76% to $77000.0 in 2023, then fell by 2.6% to $75000.0 in 2024, then slipped by 2.67% to $73000.0 in 2025, then changed by 0.0% to $73000.0 in 2026.
- Business Quant data shows LXEO's Depreciation & Amortization (CF) at $73000.0 in Q1 2026, $73000.0 in Q4 2025, and $73000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Lexeo Therapeutics | 379.94 Mn | 379.94 Mn | - | 73,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 73,000.00 |
| Mar 31, 2026 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Dec 31, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Sep 30, 2025 | 73,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Jun 30, 2025 | 62,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Mar 31, 2025 | 60,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Dec 31, 2024 | 75,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Mar 31, 2024 | 69,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Dec 31, 2023 | 77,000.00 |